Whitefort Capital Increases Economic Exposure to Arbutus Biopharma to 9.8% via Swap Agreement
Summary
Whitefort Capital Master Fund, LP, an institutional investor, has increased its total economic exposure to Arbutus Biopharma Corp to 9.8% of outstanding shares through a new cash-settled total return swap agreement.
Key Events
-
Increased Economic Exposure
Whitefort Capital Master Fund, LP increased its total economic exposure to Arbutus Biopharma Corp from 8.0% to 9.8% of outstanding shares.
-
Swap Agreement Initiated
The increase in exposure is primarily due to a new cash-settled total return swap agreement for 3,500,000 notional shares, with a reference price of $4.28, entered into on April 27, 2026.
-
Maintained Beneficial Ownership
The institutional investor maintained its direct beneficial ownership of 15,794,261 shares, representing 8.0% of the company.
Analysis
This Schedule 13D/A filing indicates that Whitefort Capital Master Fund, LP, while maintaining its 8.0% beneficial ownership, has entered into a cash-settled total return swap for 3.5 million notional shares. This transaction effectively increases their overall economic exposure to Arbutus Biopharma to 9.8% of the outstanding shares. This move by a significant institutional investor, following recent positive news such as the FDA Fast Track designation and a major patent settlement, suggests continued confidence in the company's prospects. Investors should view this as a positive signal of sustained institutional interest.
At the time of this filing, ABUS was trading at $4.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $817.3M. The 52-week trading range was $2.94 to $5.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.